We are live on ! Find out more
HARP

Harpoon Therapeutics, Inc. Common Stock
HARP

Delisted

HARP was delisted on the 8th of March, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Harpoon Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 41 → 0 (-41)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $175M → $0 (-$175M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 41

392.07% less ownership

Funds ownership: 392.07% → 0% (-392%)

Holders
–
Holders Change
-41
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
41
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$22.6M
2
NLVP
New Leaf Venture Partners
New York
-$21.1M
3
CC
Commodore Capital
New York
-$17.1M
4
RCM
RA Capital Management
Massachusetts
-$17.1M
5
Franklin Resources
Franklin Resources
California
-$17M

HARP Hedge Fund Activity: Q1 2024 in Review

0 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q1 2024, worth a combined $0 — down 100% from $175M a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of HARP and 0 opened new positions — a net loss of 41 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Cormorant Asset Management, exiting entirely with an estimated $22.6M sold.

  • 0 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q1 2024, down from 41 in Q4 2023.
  • Funds reported $0 of Harpoon Therapeutics, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q1 2024 and 41 closed out, a net change of -41 holders.
  • The largest Harpoon Therapeutics, Inc. Common Stock seller in Q1 2024 was Cormorant Asset Management, an estimated $22.6M sold.

Based on aggregated 13F filings for Q1 2024.